DolCas Biotech LLC has signed an agreement with Tenshi Kaizen Private Ltd., a specialty pharmaceutical company, to create a joint venture company called DolCas-Tenshi Bioceuticals Inc.
DolCas Biotech, LLC (Landing, NJ) and Tenshi Kaizen Private, Ltd. (Bengaluru, India) have signed an agreement to create a joint venture company called DolCas-Tenshi Bioceuticals, Inc. The joint venture company will focus exclusively on the research, development, and commercialization of novel nutraceutical lines for the U.S., Canadian, European, and Japanese markets.
“Tenshi is delighted to partner with DolCas to build a significant branded dietary supplement business for the global markets. We strongly believe that DolCas’ legacy and reputation of bringing to market science-led dietary supplements offers the perfect complement to Tenshi’s development platform for its novel ingredients,” says Venkat Iyer, co-founder of Tenshi, in a press release. “With DolCas’ exemplary go-to-market abilities, the synergies of the two partners will accelerate the development of, and accessibility to, affordable, high quality nutraceuticals.”
“The new company will operate with full vertical integration to ensure maximum transparency for our clients and consumers,” explains K G Rao, president of DolCas Biotech, in a press release. “Borrowing from pharma’s highly standardized manufacturing processes and strict regulatory guidelines and expectations, I see this venture contributing to the dietary supplement landscape in a distinctive way.”
DolCas-Tenchi Bioceuticals, Inc. will makes its first appearance, exhibiting at Vitafoods Europe, where company expects to debut two new branded ingredients.